Hinova Pharmaceuticals has received the US FDA Fast Track Designation for its drug candidate, HP518, for the treatment of Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC).
HP518 is an oral AR PROTAC protein degrader that degrades wild-type AR and clinically relevant AR ligand-binding domain (LBD) mutants, including L702H. It is currently in Phase I/II clinical trials conducted in China for patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). With the Fast Track Designation, the company plans to accelerate the development and commercialization of HP518 to improve patient outcomes.
Hinova Pharmaceuticals is a biopharmaceutical company based in China, specializing in developing drugs using PROTAC (proteolysis-targeting chimera) and deuteration technology. The company focuses on creating therapeutics for oncology and metabolic diseases. Its pipeline includes several drug candidates, such as HC-1119 for castration-resistant prostate cancer, HP501 for hyperuricemia, and HP518, an androgen receptor degrader. Hinova's research platforms include targeted drug discovery and validation, as well as lead compound optimization screening.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.